Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
But half the responses with the KRAS G12D inhibitor zoldonrasib are unconfirmed.
But sasanlimab's use looks set to remain narrow.
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
Can activity at CTLA-4 be added to PD-1 x VEGF blockade?
